Profile

Contact Details

Phone: 64 3 364 3603
Email: ruth.savage@otago.ac.nz

University Links

Position: Senior Lecturer
Department: Department of Primary Health Care (Christchurch)
Qualifications: MB BS MSc
Research summary: Medical Assessor for the New Zealand Pharmacovigilance Centre

Research

Ruth undertakes research in adverse drug reaction monitoring (pharmacovigilance) and rational prescribing and has experience in pharmacoepidemiology studies.

Ruth is also Senior Medical Assessor in the Centre for Adverse Reactions Monitoring (CARM), New Zealand Pharmacovigilance Centre, Dept of Preventive and Social Medicine, University of Otago, Dunedin where a high proportion of the suspected adverse reaction reports submitted by health professionals are from primary care. She is also an expert advisor to the New Zealand Medicines Adverse Reactions Committee. As a consultant to the Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden Ruth also undertakes research and provides training in international pharmacovigilance.

Publications

Sandberg, L., Vidlin, S. H., K-Pápai, L., Savage, R., Raemaekers, B. C., Taavola-Gustafsson, H., … Ellenius, J. (2025). Uncovering pregnancy exposures in pharmacovigilance case report databases: A comprehensive evaluation of the VigiBase pregnancy algorithm. Drug Safety, 48, 1103-1118. doi: 10.1007/s40264-025-01559-0 Journal - Research Article

Savage, R., & Lee, J. (2025, March). Ten serious drug reactions to watch for. Verbal presentation at the Annual Goodfellow Symposium, Auckland, New Zealand. Conference Contribution - Verbal presentation and other Conference outputs

Lee, J., & Savage, R. (2024, July). Primary care and pharmacovigilance: Contributions from primary care to the New Zealand Centre for Adverse Reactions Monitoring (CARM) provide examples of collaborative opportunities to increase patient and medicines safety. Verbal presentation at the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice, Te Whanganui-a-Tara Wellington, New Zealand. Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., & Lee, J. (2024, March). Tens serious drug reactions to watch out for. Verbal presentation at the Goodfellow Symposium: Skills for Next Monday, Auckland, New Zealand. Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., Lee, J., & Tatley, M. (2023). Impact of general practice on medicine and vaccine safety in New Zealand. Australian Journal of General Practice, (Suppl. 2), (pp. 238). Retrieved from https://www1.racgp.org.au/ajgp/home Conference Contribution - Published proceedings: Abstract

2025

Journal - Research Article

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., & Lee, J. (2025, March). Ten serious drug reactions to watch for. Verbal presentation at the Annual Goodfellow Symposium, Auckland, New Zealand.

2024

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., & Lee, J. (2024, March). Tens serious drug reactions to watch out for. Verbal presentation at the Goodfellow Symposium: Skills for Next Monday, Auckland, New Zealand.

2023

Journal - Research Article

Gauffin, O., Brand, J. S., Vidlin, S. H., Sartori, D., Asikainen, S., Català, M., … Savage, R., … Norén, G. N. (2023). Supporting pharmacovigilance signal validation and prioritization with analyses of routinely collected health data: Lessons learned from an EHDEN Network study. Drug Safety, 46, 1335-1352. doi: 10.1007/s40264-023-01353-w

Rudolph, A., & Savage, R. (2023). Vulval aphthous ulcers in adolescents following COVID-19 vaccination: Analysis of an international case series. Journal of Pediatric & Adolescent Gynecology, 36, 383-392. doi: 10.1016/j.jpag.2023.03.006

Conference Contribution - Published proceedings: Abstract

Savage, R. L. (2023). Empagliflozin and necrotising fasciitis of the perineum (Fournier’s gangrene): Potential risk factors in New Zealand adverse reaction reports. Proceedings of the New Zealand Primary Health Care, General Practice & Rural Health Research Symposium. (pp. 10). Retrieved from https://www.otago.ac.nz/wellington/departments/primaryhealthcaregeneralpractice

2022

Chapter in Book - Research

Savage, R. L. (2022). The value of complementary approaches to causality assessment for individual case safety reports: The example of Artemisia annua and hepatotoxicity. In J. Barnes (Ed.), Pharmacovigilance for herbal and traditional medicines. (pp. 211-220). Cham, Switzerland: Springer. doi: 10.1007/978-3-031-07275-8

2021

Journal - Research Article

Wilson, G., Windner, Z., Bidwell, S., Dowell, A., Toop, L., Savage, R., & Hudson, B. (2021). Navigating the health system during COVID-19: Primary care perspectives on delayed patient care. New Zealand Medical Journal, 134(1546), 17-27. Retrieved from https://www.nzma.org.nz/journal

Wilson, G., Windner, Z., Bidwell, S., Currie, O., Dowell, A., Halim, A. A., Toop, L., Savage, R., Ranaweera, U., Beadel, H., & Hudson, B. (2021). 'Here to stay': Changes to prescribing medication in general practice during the COVID-19 pandemic in New Zealand. Journal of Primary Health Care, 13(3), 222-230. doi: 10.1071/hc21035

Rocca, E., Gauffin, O., Savage, R., Vidlin, S. H., & Grundmark, B. (2021). Remdesivir in the COVID-19 pandemic: An analysis of spontaneous reports in VigiBase during 2020. Drug Safety, 44, 987-998. doi: 10.1007/s40264-021-01091-x

Wilson, G., Currie, O., Bidwell, S., Saeed, B., Dowell, A., Halim, A. A., Toop, L., Richardson, A., Savage, R., & Hudson, B. (2021). Empty waiting rooms: The New Zealand general practice experience with telehealth during the COVID-19 pandemic. New Zealand Medical Journal, 134(1538), 89-101. Retrieved from https://www.nzma.org.nz/journal

Russom, M., Fitsum, Y., Abraham, A., & Savage, R. L. (2021). Diclofenac and the risk of rhabdomyolysis: Analysis of publications and the WHO Global Pharmacovigilance Database. Drugs: Real World Outcomes, 8, 263-275. doi: 10.1007/s40801-021-00240-z

Journal - Research Other

Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020

Conference Contribution - Published proceedings: Abstract

Savage, R., Vidlin, S. H., Grundmark, B., Rocca, E., & Gauffin, O. (2021). Remdesivir and renal injury: Interpreting global case safety reports in the context of COVID-19 infection. Proceedings of the 6th Pharmacoepidemiology Research Network Symposium. (pp. 11-12). Retrieved from https://www.otago.ac.nz/pharmacoepidemiology

2020

Journal - Research Article

Hegerius, A., Caduff-Janosa, P., Savage, R., & Ellenius, J. (2020). E-learning in pharmacovigilance: An evaluation of microlearning-based modules developed by Uppsala Monitoring Centre. Drug Safety, 43, 1171-1180. doi: 10.1007/s40264-020-00981-w

2019

Journal - Research Article

Kuan, I. H. S., Savage, R. L., Duffull, S. B., Walker, R. J., & Wright, D. F. B. (2019). The association between metformin therapy and lactic acidosis. Drug Safety, 42, 1449-1469. doi: 10.1007/s40264-019-00854-x

Journal - Research Other

Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448

2018

Journal - Research Other

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Conference Contribution - Published proceedings: Abstract

Storey, M., Savage, R., Stenlund, J., Tatley, M., & Kenyon, S. (2018). Using the M² scheme to investigate safety signals. Proceedings of the 4th Pharmacoepidemiology Research Network Symposium. (pp. 12). Retrieved from https://www.otago.ac.nz/pharmacoepidemiology

Savage, R. L., Tatley, M., & Barnes, J. (2018). Hepatotoxicity with a natural dietary supplement, Artemisia annua L. extract in grapeseed oil. New Zealand Pharmacovigilance Centre Reports. Drug Safety, 41(11), (pp. 1151). doi: 10.1007/s40264-018-0719-2

Hegerius, A., Caduff, P., Savage, R., & Ellenius, J. (2018). Anywhere, anytime: Distance learning in pharmacovigilance. Drug Safety, 41(11), (pp. 1109). doi: 10.1007/s40264-018-0719-2

Conference Contribution - Verbal presentation and other Conference outputs

Kuan, I. H. S., Duffull, S. B., Savage, R. L., & Wright, D. F. B. (2018, August). Should we use metformin in patients with chronic renal impairment? A systematic review of published metformin associated lactic acidosis cases. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2017

Journal - Research Other

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Conference Contribution - Published proceedings: Abstract

Savage, R., & Tatley, M. (2017). Rapid onset of very high INR values when roxithromycin prescribed with warfarin challenges the accepted mechanism. Drug Safety, 40(10), (pp. 963-964). doi: 10.1007/s40264-017-0580-8

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., Tatley, M., & Kunac, D. (2017, July). Fifty years of adverse drug reaction reporting in New Zealand: Primary care involvement and the developing use of e-health. Verbal presentation at the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice Quality Symposium, Dunedin, New Zealand.

2016

Journal - Research Article

Maggo, S. D. S., Savage, R. L., & Kennedy, M. A. (2016). Impact of new genomic technologies on understanding adverse drug reactions. Clinical Pharmacokinetics, 55(4), 419-436. doi: 10.1007/s40262-015-0324-9

Journal - Research Other

Castellano, M., Sartori, D., & Savage, R. (2016). Dabigatran and thromboembolism: Analysis of case histories for risk factors. WHO Pharmaceuticals Newsletter, 3, 15-22. Retrieved from http://www.who.int/medicines/publications/newsletter/en/

Savage, R. (2016). Vemurafenib and atrial fibrillation: Signal strengthening. WHO Pharmaceuticals Newsletter, 1, 17-22. Retrieved from http://www.who.int/medicines/publications/newsletter/en/

Conference Contribution - Published proceedings: Abstract

Savage, R., Star, K., Zekarias, A., Persson Brobert, G., Ansell, D., & Edwards, I. R. (2016). Prescribing and diagnostic issues associated with sumatriptan identified through open-ended screening for safety signals in electronic health care records. Drug Safety, 39(10), (pp. 1014-1015). doi: 10.1007/s40264-016-0445-6

Tatley, M., Savage, R., Kunac, D., & Ashton, J. (2016). Years of pharmacovigilance in New Zealand: Lessons in sustainability and growth. Drug Safety, 39(10), (pp. 1001). doi: 10.1007/s40264-016-0445-6

Savage, R., Clark, P., & Tatley, M. (2016). Taking a fresh look at identifying and responding to drug-induced illness. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice. Retrieved from http://www.generalpractice.org.nz/gp16

2015

Journal - Research Article

Savage, R. L., Zekarias, A., & Caduff-Janosa, P. (2015). Varenicline and abnormal sleep related events. Sleep, 38(5), 833-837. doi: 10.5665/sleep.4686

Journal - Research Other

Wells, J. E., Cross, N. B., Savage, R. L., Parkin, L., Horsburgh, S., & Richardson, A. K. (2015). Renal replacement therapy associated with lithium nephrotoxicity in New Zealand. New Zealand Medical Journal, 128(1425). Retrieved from http://www.nzma.org.nz/journal

Savage, R. (2015). Brentuximab and hepatic disorders. WHO Pharmaceuticals Newsletter, 2, 17-22. Retrieved from http://www.who.int/medicines/publications/PharmaNewsletter2_15/en/

Conference Contribution - Published proceedings: Abstract

Savage, R., & Tatley, M. (2015). Comparison of New Zealand and international spontaneous reports of adverse reactions occurring within one week of zoledronic acid infusion with the information in New Zealand product data sheets. In J. Young (Ed.), Proceedings of the Annual General Practice and Primary Care Research Weekend. (pp. 27-28). Dunedin, New Zealand: Department of General Practice and Rural Health, University of Otago. [Abstract]

2014

Journal - Research Other

Savage, R. (2014). Tocilizumab: Psoriasis and aggravated psoriasis. WHO Pharmaceuticals Newsletter, 2, 16-21. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter2_14/en/

Conference Contribution - Published proceedings: Abstract

Savage, R. L., Zekarias, A., & Caduff-Janosa, P. (2014). Varenicline and abnormal sleep-related events. Drug Safety, 37(10), (pp. 878-879). doi: 10.1007/s40264-014-0208-1

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. (2014, August). Varenicline and abnormal sleep-related events. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2013

Journal - Research Other

Savage, R. (2013). Donepezil: Syncope, heart block and beta-adrenergic blockade. Prescriber Update, 34(3), 30. Retrieved from http://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2013). The New Zealand Centre for Adverse Reactions Monitoring: A source of practice-based evidence. Journal of Primary Health Care, 5(2), 170-173. doi: 10.1071/HC13170

Conference Contribution - Published proceedings: Abstract

Savage, R. L. (2013). The New Zealand Centre for Adverse Reactions Monitoring: A source of practice-based evidence. Clinical Therapeutics, 35(8, Suppl.), (pp. e128). doi: 10.1016/j.clinthera.2013.07.400

Sallstedt, L., Watson, S., Savage, R. L., & Zekarias, A. (2013). Follow up of UMC signals. Drug Safety, 36(9), (pp. 888). doi: 10.1007/s40264-013-0087-x

Savage, R. L. (2013). The New Zealand centre for adverse drug reactions monitoring: A source of practice-based evidence. Clinical Therapeutics, 35(8 (Suppl.)), (pp. e128). doi: 10.1016/j.clinthera.2013.07.400

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. (2013, October). Varenicline and abnormal sleep-related events. Verbal presentation at the Hanmer Springs Research Weekend, Hanmer Springs, New Zealand.

Kennedy, M. A., Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., … Miller, A. (2013, August). Genomic medicine and adverse drug reactions. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.

Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., Helsby, N. A., Miller, A., & Kennedy, M. A. (2013, August). Understanding adverse Drug Reactions or responses Using Genomic Sequencing (UDRUGS). Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2012

Journal - Research Article

Savage, R. L., Star, K., & Hill, R. (2012). Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis. International Journal of Risk & Safety in Medicine, 24(4), 215-219. doi: 10.3233/jrs-2012-0577

Harrison-Woolrych, M., Maggo, S., Tan, M., Savage, R., & Ashton, J. (2012). Cardiovascular events in patients taking varenicline: A case series from intensive postmarketing surveillance in New Zealand. Drug Safety, 35(1), 33-43. doi: 10.2165/11597690-000000000-00000

Journal - Research Other

Savage, R. (2012). Dronedarone, hyperthyroidism and decreased thyroid stimulating hormone. WHO Pharmaceuticals Newsletter, 4, 14-18. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter4_12/en/

Savage, R. (2012). Venlafaxine, pre-eclampsia, eclampsia and related disorders of pregnancy. WHO Pharmaceuticals Newsletter, 1, 19-22. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter1_12/en/

Conference Contribution - Published proceedings: Abstract

Savage, R. (2012). Proposal from the New Zealand Pharmacovigilence Centre for a GPEP1 module in adverse drug reaction monitoring and safe and rational prescribing. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice: Through Patients' Eyes. Retrieved from http://www.conference.co.nz/gp12/programme/index

Conference Contribution - Verbal presentation and other Conference outputs

Kennedy, M. A., Chua, E. W., Barclay, M. L., & Savage, R. (2012, November). Growing a New Zealand biobank (UDRUGS) to allow genetic analysis of rare, serious adverse drug reactions and unusual drug responses. Verbal presentation at the 8th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Savage, R. (2012, August). Evaluation of 10 years of drug-related hyponatraemia reports in the New Zealand Centre for Adverse Reactions Monitoring (CARM) database, 2001-2010. Verbal presentation at the Primary Care and General Practice Research Weekend, Martinborough, New Zealand.

2010

Journal - Research Other

Savage, R. L. (2010). Leflunomide in combination therapy for rheumatoid arthritis [Editorial]. Drug Safety, 33(6), 523-526. doi: 10.2165/11532390-000000000-00000

Conference Contribution - Published proceedings: Abstract

Savage, R. (2010). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the CARM database. Proceedings of the New Zealand General Practitioners Conference: Doing the right thing. (pp. 45). Retrieved from http://www.conference.co.nz/rnzcgp10/programme

Savage, R. L. (2010). Can serious drug-related hyponatraemia be avoided? Changing patterns in spontaneous reports of medicine-related hyponatraemia lead to new prescribing advice. Drug Safety. 33(10), (pp. 943). [Abstract]

Savage, R. L. (2010). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the New Zealand Pharmacovigilance Centre. Drug Safety. 33(10), (pp. 952). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. (2010, September). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the CARM database. Verbal presentation at the New Zealand General Practitioners Conference Research Day: Doing the Right Thing, Christchurch, New Zealand.

Savage, R. (2010, November). Etoricoxib & NSAID guidelines. Verbal presentation at the GP Research Weekend, Dunedin, New Zealand.

2009

Journal - Research Article

Savage, R. L., Kunac, D. L., & Johansson, J. (2009). Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain. Current Anaesthesia & Critical Care, 20(5-6), 215-220. doi: 10.1016/j.cacc.2009.07.013

Conference Contribution - Published proceedings: Abstract

James, C. M., Tatley, M., Savage, R., Kenyon, S. H., & Jessamine, S. (2009). Eltroxin formulation change: The New Zealand experience. Drug Safety, 32(10), (pp. 900). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. (2009, October). Identification and analysis of preventable adverse drug events in primary care through reports to the Centre for Adverse Reactions Monitoring (CARM). Verbal presentation at the Waitomo General Practitioners Research Weekend, Waitomo, New Zealand.

Savage, R. (2009, September). Can severe medicine-related hyponatraemia be avoided. Verbal presentation at the Royal New Zealand College of General Practitioners Annual Scientific Conference: Myths and Realities of Primary Care, Wellington, New Zealand.

Savage, R. L. (2009, September). Changing patterns in spontaneous reports of medicine-related hyponatraemia. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.

2008

Journal - Research Article

Gwynne Jones, D. P., Savage, R. L., & Highton, J. (2008). Alendronate-induced synovitis. Journal of Rheumatology, 35(3), 537-538.

Journal - Research Other

Savage, R. (2008). Leflunomide: Update on serious toxicity. Prescriber Update, 29(1), 13-14. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2008). Tumour necrosis factor inhibitors: Recognise and treat infection promptly. Prescriber Update, 29(1), 5-6. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Meyboom, R. H. B., Star, K., Bate, J., Savage, R., & Edwards, I. R. (2008). TNF-α inhibitors and leukaemia: International pharmacovigilance reports [Letter to the editor]. Drug Safety, 31(5), 445-447. doi: 10.2165/00002018-200831050-00013

Conference Contribution - Published proceedings: Abstract

Maggo, S., Savage, R., Ashton, J. A., & Clark, D. W. G. (2008). Retrospective analysis of psychiatric effects reported for HMG-COA reductase inhibitors (STATINS) at the NZPHVC. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf

Savage, R. (2008). Emerging safety signals for leflunomide from a regulatory review. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf

2007

Journal - Research Article

Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.

Jenks, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in rheumatoid arthritis. Journal of Rheumatology, 34, 2201-2203.

Journal - Research Other

Savage, R. (2007). Glitazones: Fluid retention, cardiac failure and macular oedema. Prescriber Update, 28(1), 8-10. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2007). Serious reactions with tramadol: Seizures and serotonin syndrome. Prescriber Update, 28(1), 11-13. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Conference Contribution - Published proceedings: Abstract

Savage, R. L., & Tatley, M. (2007). Pancreatitis with serious sequelae in patients taking ezetimibe. Drug Safety, 30(10). [Abstract]

Meuli, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in RA. Internal Medicine Journal. 37(Suppl. 2), (pp. A48). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. L. (2007, August-September). Emerging safety signals for leflunomide from a systemic analysis of spontaneous reporting systems, publications and international regulation. Verbal presentation at the New Zealand Rheumatology Association Conference, Dunedin, New Zealand.

Other Research Output

Savage, R. (2007, December). The safety of Rosiglitazone and other Thaizolidinediones: Signals of paradoxical adverse reactions from national and international spontaneous reports. Festschrift in honour of Associate Professor David Clark: An international symposium on New Zealand's crucial role in monitoring/improving the safety of medicines. Dunedin, New Zealand. [Public Seminar].

2006

Journal - Research Article

Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. (2006). Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Internal Medicine Journal, 36, 162-169.

Journal - Research Other

Savage, R. (2006). Leflunomide and pneumonitis. Prescriber Update, 27(1), 7-8. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2006). Alendronate and inflammatory adverse reactions. Prescriber Update, 27(1), 4-6. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2006). Evidence for tramadol-warfarin interaction. Prescriber Update, 27(2), 23-24. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Professional & Other Non-Research Articles

Savage, R. (2006). Interstitial nephritis with PPIs on the rise. New Zealand Doctor, (October), 22.

Conference Contribution - Published proceedings: Abstract

Savage, R. L., & Tatley, M. (2006). Method for developing an adverse reaction profile for a medicine using national and international spontaneous reports. Drug Safety. 29(10), (pp. 964). [Abstract]

2005

Journal - Research Article

Savage, R. (2005). Thiazolidinediones and lowered high density lipoprotein cholesterol. WHO Signal, February, 6-8.

Gwynne Jones, D., Savage, R., & Highton, J. (2005). Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ, 330, 7482, 74. doi: 10.1136/bmj.330.7482.74

Savage, R. (2005). Cyclo-oxygenase-2 inhibitors: When should they be used in the elderly? Drugs & Aging, 22(3), 185-200.

Journal - Research Other

Savage, R., & Rademaker, M. (2005). Topical corticosteroids: Face facts. Prescriber Update, 26(2), 30-31. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. L., & Kiuru, A. (2005). Thiazolidinediones and lowered HDL cholesterol [Research Letter]. Diabetes Care, 28(9), 2329-2330.

Ng, J., Savage, R., & McQueen, F. (2005). Churg-Strauss vasculitis syndrome and leukotriene receptor antagonists [Research Letter]. Annals of the Rheumatic Diseases, 64, 1382.

Conference Contribution - Published proceedings: Abstract

Savage, R. L., & Kiuru, A. (2005). Rosiglitazone and lowered high density lipoprotein cholesterol. Drug Safety. 28(10), (pp. 950). [Abstract]

Savage, R. L., Star, K., & Edwards, I. R. (2005). Is rofecoxib different and do COX-2 inhibitors have advantages over standard NSAIDS? An analysis of international voluntary adverse reaction reports. Drug Safety. 28(10), (pp. 950). [Abstract]

Savage, R. L., Coulter, D. M., & Harrison-Woolrych, M. (2005). COX-2 inhibitors may cause dysrrhythmias: A signal from the New Zealand Intensive Medicines Monitoring Programme. Drug Safety. 28(10), (pp. 963). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. T. (2005, September). Pneumonitis with leflunomide: A profile of New Zealand and Australian reports. Verbal presentation at the New Zealand Rheumatology Association in conjunction with NZ Health Professionals in Rheumatology Annual Scientific Meeting, Palmerston North, New Zealand.

Savage, R. L., & Kiuru, A. (2005, August). Rosiglitazone and lowered HDL cholesterol. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

Savage, R. L. (2005, August). Tramadol and hepatitis: A signal from spontaneous reports. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

2004

Journal - Research Other

Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Conference Contribution - Published proceedings: Abstract

Savage, R. L., Highton, J., Chapman, P. T., & Boyd, I. W. (2004). Severe pneumonitis with leflunomide: Features of reports from New Zealand and Australia. Clinical and Experimental Pharmacology and Physiology. 31(Suppl.), (pp. A232). [Abstract]

Conference Contribution - Poster Presentation (not in published proceedings)

Ericsson, J., Savage, R., Farah, M., & Meyboom, R. (2004, October). Failure of oral contraceptives during the use of hypericum-containing drugs. Poster session presented at the 4th Annual Meeting of the International Society of Pharmacovigilance, Dublin, Ireland.

Savage, R. L., Highton, J., Chapman, P. T., & Boyd, I. W. (2004). Severe pneumonitis with leflunomide: New Zealand and Australian adverse reaction reports. Poster session presented at the Clinical Pharmacology and Therapeutics International Meeting, Brisbane, Australia.

Commissioned Report for External Body

Savage, R. (2004). Can infliximab aggravate a silent breast cancer? Commissioned by World Health Organisation (WHO) Signal, June 2004. Sweden: Uppsala Monitoring Centre. 3p.

2003

Journal - Research Article

Coulter, D. M., Clark, D. W., & Savage, R. (2003). Celecoxib, rofecoxib, and acute temporary visual impairment. British Medical Journal, 327, 1214-1215.

Conference Contribution - Published proceedings: Abstract

Savage, R. L., & Boyd, I. W. (2003). Administration error may be the cause of severe back pain with intravenous amiodarone. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Scientific Meeting. Wellington, New Zealand. [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R. L. (2003, February). Experience of international drug monitoring. Verbal presentation at the International Workshop on Pharmacoepidmiology, Otago Museum, Dunedin, New Zealand. Geneva, Switzerland: World Health Organization.

Savage, R. L. (2003, August). How pharmacovigilance contributes to quality use of medicines. Verbal presentation at the ASCEPT Scientific Meeting, Wellington, New Zealand. Geneva, Switzerland: World Health Organization.

2002

Journal - Research Article

Savage, R. (2002). Proton pump inhibitors. WHO Pharmaceuticals Newsletter, (2), 12.

Savage, R. (2002). Loratadine. WHO Pharmaceuticals Newsletter, (2), 12.

Journal - Research Other

Savage, R. (2002). A dangerous trio. Prescriber Update, 23(2), 20. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2002). Can patients stomach COX-2 inhibitors? Prescriber Update, 23(2), 18-19. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2002). Venous thromoembolism with Diane 35^TM and Estelle 35^TM. Prescriber Update, 23(1), 2-3. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Professional & Other Non-Research Articles

Pettersson, M., & Savage, R. L. (2002). Cyclo-oxygenase 2 inhibitors and sudden death. Drugs of Current Interest, (December). USA: Uppsala Monitoring Centre.

Conference Contribution - Published proceedings: Abstract

Savage, R., & Uppsala Monitoring Centre. (2002). COX-2 Inhibitors and sudden death. Drugs of Current Interest - Abstracts. (pp. 15). Sweden: the Uppsala Monitoring Centre. [Abstract]

2001

Journal - Research Other

Savage, R. (2001). NSAIAs can cause lower GIT damage. Prescriber Update, 21, 25-27. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Savage, R. (2001). Tiaprofenic acid-induced cystitis. Prescriber Update, 22, 18-21. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Conference Contribution - Published proceedings: Abstract

Savage, R., Boyd, I., & Coulter, D. M. (2001). Celecoxib and tricyclic antidepressants (TCAs). Report of the 24th Annual Meeting of Representatives of the National Centres participating in the WHO International Drug Monitoring Programme. (pp. 10). Dunedin, New Zealand: WHO. [Abstract]

Savage, R. L., Boyd, I., & Coulter, D. (2001). Celecoxib: An adverse reaction profile. Proceedings of the Australian Society of Clinical and Experimental Pharmacologists and Toxicologists Annual Scientific Meeting. 9, (pp. 51). Dunedin, New Zealand. [Abstract]

2000

Journal - Research Article

Savage, R., & Coulter, D. M. (2000). Oral contraceptives and venous thromboembolism [Letter]. New Ethicals Journal, 24.

Journal - Research Other

Savage, R. (2000). Omeprazole-induced interstitial nephritis. Prescriber Update, 20, 11-13. Retrieved from https://www.moh.govt.nz

1997

Journal - Research Article

The ADR Signals Analysis Project (ASAP) Team, including Savage, R. (1997). How does cystitis affect a comparative risk profile of tiaprofenic acid with other nonsteroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacology & Toxicology, 80(5), 211-217. doi: 10.1111/j.1600-0773.1997.tb01962.x

Journal - Research Other

Savage, R. (1997). Oral contraceptives and venous thromboembolism [Letter]. New Zealand Medical Journal, 107, 109.

Savage, R. (1997). Current debate: Oral contraceptives and venous thromboembolism. PreMec Bulletin, November.